


Carrat F, Fontaine H, Dorival C. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral


Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV)


Esmat GE, Doss WH, Qaqish RB, Waked I, Shiha GE, Yosry A, et al. Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II)


Fernandez-Carrillo C, Lens S, Llop E, Pascasio JM, Fernandez I, Ballellas C, et al. Treatment of hepatitis C virus in...


Geng X-X, Huang R-G, Lin J-M, Jiang N, Yang X-X. Transient elastography in clinical detection of liver cirrhosis: a...


Harrison DS, Giang J, Darling JM. An interaction between glecaprevir, pibrentasvir, and colchicine causing


paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385(9986):2502-2509.


Jiang Y, Nwankwo C. Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug in...


Kramer JR, Puenpatom A, Erickson KF, et al. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in...


Lange B, Roberts T, Cohn J. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693.


Lawitz EJ, Gane EJ, Pearlman B, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-1086.


Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR


Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016;


Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540.


analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69(2):293-300.


Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to


Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination


Information sheet on naltrexone therapy [Internet]. Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone


Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Shelton BA, Sawinski D, Mehta S, Reed RD, MacLennan PA, Locke JE. Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. Transpl Infect Dis. 2018;20:e12829.


Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.


Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-

Prescription drug pricing in the private sector. 2015.


